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tExperimental studies suggesting that cardiac
ransfer of unfractionated bone marrow cells
BMCs) or bone marrow–derived stem and progen-
tor cells enhances functional recovery after myo-
ardial infarction have caused much excitement
1-4]. On the basis of these studies and the more
eneral concept of adult stem cell plasticity, it has
een proposed that bone marrow–derived stem and
rogenitor cells may be used for cardiac tissue re-
air in patients after acute myocardial infarction
1,5]. Early clinical investigations indicate that in-
usion of autologous BMCs into the infarct-related
oronary artery is feasible after acute myocardial
nfarction [6,7]. However, because of the nonran-
omized design of these studies, the efﬁcacy of
ntracoronary BMC transfer for functional recovery
fter myocardial infarction in patients has remained
ncertain. We conducted a prospective, random-
zed, controlled trial to determine the effect of in-
racoronary autologous BMC transfer on left ven-
ricular functional recovery in patients after acute
yocardial infarction and successful percutaneous
oronary intervention (PCI) [8]. After successful
CI for acute ST segment elevation myocardial
nfarction, we randomized patients to a control
roup (30 patients) that received optimal postin-
arction medical therapy and a BMC transfer group
30 patients) that received optimal medical therapy
nd intracoronary transfer of autologous BMCs 5
ays after PCI. The left ventricular ejection fraction
LVEF) change from baseline to 6-month follow-
p, as determined by cardiac magnetic resonance
maging, was the prespeciﬁed primary end point of
he trial. After 6 months, the LVEF had increased o
B & M Ty 0.7 percentage points in the control group and
.7 percentage points in the BMC transfer group (P
.0026). BMC transfer enhanced left ventricular
ystolic function primarily in the infarct border
one. The improvement in global LVEF at 6-month
ollow-up was not correlated with the number of
ucleated cells, CD34 cells, or hematopoietic col-
ny-forming cells infused into the infarct-related
oronary artery. BMC transfer did not increase the
isk of adverse clinical events, including in-stent
e-stenosis or proarrhythmic effects. We now have
lso used labeling of BMCs and positron emission
omography scanning to monitor the homing of
hese cells into the myocardium after infarction in a
ubset of patients and identiﬁed labeled cells within
he infarcted myocardium. These studies suggest
hat only a fraction of cells infused into the coro-
ary circulation are homing in the heart. It is inter-
sting to note that the percentage of homing cells
an be enhanced by selection of bone marrow–
erived CD34 cells, and the latter approach is
ssociated with preferential homing into the infarct
order zone. We are currently performing pro-
onged follow-up studies of our patients to establish
he long-term safety and efﬁcacy of this therapeutic
ntervention (Figure 1).
Our studies suggest that intracoronary transfer
f autologous BMCs seems safe and promotes im-
rovement of left ventricular systolic function in
atients after acute myocardial infarction. However,
arge double-blind randomized trials are required to
how a beneﬁcial effect not only on ejection frac-
ion, but also on clinical end points and, ultimately,
n survival. Such studies involving 200 patients are
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8ow under way or are about to start. In the mean-
hile, experimental studies are mandatory to eluci-
ate the underlying mechanisms, which most likely
re not conﬁned to the differentiation of these cells
nto cardiomyocytes [9,10] but rather expand to the
aracrine effects of the cells applied [11,12].
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